Display options
Cite
Rahmani R, Eivazi N, Paknejad M, et al. A theoretical strategy for acceleration of human immune response against SARS-CoV-2: a fusion protein harboring virus-binding and pre-exposed antigen domains. Virusdisease. 2021;1-4doi: 10.1007/s13337-021-00704-4.
Rahmani, R., Eivazi, N., Paknejad, M., & Aminian, M. (2021). A theoretical strategy for acceleration of human immune response against SARS-CoV-2: a fusion protein harboring virus-binding and pre-exposed antigen domains. Virusdisease, 1-4. https://doi.org/10.1007/s13337-021-00704-4
Rahmani, Reza, et al. "A theoretical strategy for acceleration of human immune response against SARS-CoV-2: a fusion protein harboring virus-binding and pre-exposed antigen domains." Virusdisease vol. (2021): 1-4. doi: https://doi.org/10.1007/s13337-021-00704-4
Rahmani R, Eivazi N, Paknejad M, Aminian M. A theoretical strategy for acceleration of human immune response against SARS-CoV-2: a fusion protein harboring virus-binding and pre-exposed antigen domains. Virusdisease. 2021 Jul 13;1-4. doi: 10.1007/s13337-021-00704-4. Epub 2021 Jul 13. PMID: 34277894; PMCID: PMC8275912.
Copy Download .nbib Format: NLM
Share it on

Virusdisease. 2021 Jul 13;1-4. doi: 10.1007/s13337-021-00704-4. Epub 2021 Jul 13.

A theoretical strategy for acceleration of human immune response against SARS-CoV-2: a fusion protein harboring virus-binding and pre-exposed antigen domains.

Virusdisease

Reza Rahmani, Neda Eivazi, Maliheh Paknejad, Mahdi Aminian

Affiliations

  1. Department of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  2. Recombinant Vaccine Research Center, Tehran University of Medical Sciences, Tehran, Iran.

PMID: 34277894 PMCID: PMC8275912 DOI: 10.1007/s13337-021-00704-4

Abstract

Coronavirus disease 2019 (COVID-19) is a respiratory disease that outbreaks since December 2019 and spread globally. Various methods have been used to treat SARS-CoV-2 that is generally based on the information obtained from the therapeutic approaches used for SARS-COV and MERS patients. In this article, we introduce a theoretical strategy in which a two-domain fusion protein presents the virus to the immune system. This fusion protein contains a viral-binding domain such as the ACE2 domain and a domain such as the hepatitis B antigen that has previously been exposed to the immune system. This two-domain fusion protein, could be called "virus-presenting fusion protein", would attach to the virus spike protein via the ACE2 domain while the hepatitis B antigen would be bound by anti-hepatitis B antibodies facilitating the opsonization and presentation of the virus to the immune system. We believe that this virus-presenting fusion protein will accelerate the immune response to the SARS-CoV-2 virus.

© Indian Virological Society 2021.

Keywords: COVID-19; Fusion Protein; Pre-exposed antigen; SARS-CoV-2; Spike-binding domains

References

  1. Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5871-6 - PubMed
  2. J Reprod Immunol. 2021 Apr;144:103271 - PubMed
  3. Nature. 2005 Jul 7;436(7047):112-6 - PubMed
  4. Adv Virus Res. 2019;105:93-116 - PubMed
  5. Arch Virol. 2021 Mar;166(3):949-954 - PubMed
  6. Cell Host Microbe. 2020 Mar 11;27(3):325-328 - PubMed
  7. Clin Infect Dis. 2015 Aug 15;61(4):496-502 - PubMed
  8. J Virol. 2006 Jun;80(12):5927-40 - PubMed
  9. J Allergy Clin Immunol. 2020 Aug;146(2):325-327 - PubMed
  10. Front Immunol. 2013 Jul 29;4:217 - PubMed
  11. Science. 2020 Mar 13;367(6483):1260-1263 - PubMed
  12. Thorax. 2021 Feb 12;: - PubMed
  13. Appl Microbiol Biotechnol. 2007 Nov;77(1):13-22 - PubMed
  14. N Engl J Med. 2003 May 15;348(20):1953-66 - PubMed
  15. J Med Virol. 2020 Jul;92(7):740-746 - PubMed
  16. Eur Rev Med Pharmacol Sci. 2021 Mar;25(5):2435-2448 - PubMed
  17. Curr Pharmacol Rep. 2020 Jul 18;:1-9 - PubMed
  18. Cell Res. 2020 Mar;30(3):269-271 - PubMed
  19. Clin Dev Immunol. 2012;2012:980250 - PubMed
  20. J Biol Chem. 2004 Jan 30;279(5):3197-201 - PubMed
  21. Pharmacol Rep. 2021 Jun;73(3):736-749 - PubMed
  22. Q J Nucl Med. 1998 Dec;42(4):225-41 - PubMed
  23. Nat Rev Immunol. 2018 May;18(5):297-308 - PubMed
  24. Cells. 2021 Jan 21;10(2): - PubMed
  25. J Virol. 2020 Mar 17;94(7): - PubMed
  26. Pathogens. 2020 Mar 20;9(3): - PubMed
  27. Virusdisease. 2021 Jan 28;:1-9 - PubMed

Publication Types